Antimicrobials: mechanisms of action

Classify antimicrobials by target before memorizing spectrum

Antibacterial drugs are easier to understand when the first question is 'what bacterial process does this drug interrupt?' Cell-wall agents weaken peptidoglycan synthesis or assembly. Protein synthesis inhibitors bind ribosomal subunits. Fluoroquinolones and rifamycins interfere with DNA or RNA synthesis. TMP-SMX blocks sequential folate metabolism. Daptomycin and polymyxins disrupt membranes. This framework explains many spectrum gaps, toxicities, and treatment limitations before resistance is considered.

Beta-lactams: PBPs first, then subclasses

Penicillins, cephalosporins, carbapenems, and aztreonam all inhibit cell-wall synthesis by binding PBPs, but their clinical behavior differs by PBP affinity, gram-negative entry, beta-lactamase stability, protein binding, and pharmacodynamics. PBP specificity is useful as a teaching anchor, but it is never the whole spectrum story.

Beta-lactamase inhibitor combinations extend, but do not universalize, beta-lactams

Beta-lactamase inhibitors protect partner beta-lactams from some enzymes, but each inhibitor has a specific range. Clavulanate, sulbactam, and tazobactam improve activity against many common beta-lactamases but do not solve AmpC, ESBL, or carbapenemase problems reliably in all syndromes. Newer combinations such as ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, ceftolozane-tazobactam, and aztreonam-avibactam have organism- and mechanism-specific roles. The key bedside habit is to ask what the likely enzyme is and whether the combination was designed for it.

• Piperacillin-tazobactam: broad empiric gram-negative, anaerobic, and Enterococcus faecalis activity, but not a universal ESBL drug for invasive infection.
• Ceftolozane-tazobactam: often useful for resistant Pseudomonas depending on susceptibility.
• Ceftazidime-avibactam: activity against many KPC and OXA-48-like producers, not metallo-beta-lactamases alone.
• Aztreonam-avibactam: conceptually important for metallo-beta-lactamase producers because aztreonam resists MBL hydrolysis while avibactam protects from co-produced serine beta-lactamases.

Glycopeptides, lipopeptides, and other cell-wall agents have narrow but important roles

Vancomycin binds D-Ala-D-Ala precursors and remains central for empiric serious MRSA coverage, but it is not active against gram-negative rods and is poorly absorbed orally. Oral vancomycin is therefore an intestinal drug for C. difficile, not a systemic MRSA drug. Daptomycin depolarizes gram-positive membranes and can treat MRSA and VRE bacteremia or right-sided endocarditis, but pulmonary surfactant inactivates it, so it is not used for pneumonia. Fosfomycin blocks early cell-wall synthesis and is mainly used as an oral option for selected cystitis syndromes in the United States.

• IV vancomycin: systemic gram-positive coverage; monitor exposure and kidney risk.
• Oral vancomycin: not systemically absorbed; use is gastrointestinal, especially C. difficile.
• Daptomycin: bactericidal gram-positive agent; avoid pneumonia; monitor CPK and myopathy risk.
• Fosfomycin: urinary concentrations are the clinical advantage; do not use as bacteremia therapy.

30S inhibitors: aminoglycosides and tetracyclines are not interchangeable

Aminoglycosides bind the 30S ribosomal subunit and cause misreading of mRNA. They are concentration-dependent, nephrotoxic, ototoxic, synergistic in selected gram-positive infections, and poor in anaerobic or acidic environments because uptake requires oxygen-dependent transport. Tetracyclines also act at 30S but are primarily bacteriostatic, orally available in many cases, and clinically useful for rickettsial illness, atypical pneumonia pathogens, some MRSA skin infections, zoonoses, and selected resistant gram-negative infections depending on agent and susceptibility.

• Aminoglycosides: gentamicin, tobramycin, amikacin; peak-driven killing; kidney/ear toxicity; not anaerobic drugs.
• Doxycycline: first-line for many tick-borne rickettsial illnesses and useful for atypical pathogens.
• Minocycline/tigecycline/eravacycline: broader resistant-organism niches; understand bloodstream limitations and syndrome fit.
• Tetracycline toxicities: GI intolerance, photosensitivity, esophagitis, tooth/bone considerations in selected populations.

50S inhibitors differ by syndrome, toxicity, and oral bioavailability

Macrolides are useful for atypical respiratory pathogens and selected streptococcal infections, but resistance can limit pneumococcal use. Clindamycin has anaerobic and gram-positive activity and is often discussed for toxin suppression, but inducible resistance matters. Linezolid has excellent oral bioavailability and activity against MRSA and VRE; monitor for cytopenias, neuropathy with prolonged use, and serotonergic interactions. Chloramphenicol and streptogramins are now niche agents but remain useful for understanding ribosomal pharmacology.

• Azithromycin: atypical pneumonia coverage and selected STI/GI uses; QT and drug interaction issues matter.
• Clindamycin: selected skin/soft tissue, anaerobic, and toxin-suppression roles; C. difficile risk and D-test matter.
• Linezolid: oral equals IV exposure for practical purposes; useful step-down option when syndrome fits.
• Tedizolid: related oxazolidinone with selected ABSSSI role; less residency-core than linezolid.

DNA/RNA agents are powerful but syndrome-limited

Fluoroquinolones inhibit DNA gyrase and topoisomerase IV and have high oral bioavailability, but toxicity and resistance concerns mean they should not be reflexive convenience drugs. Rifamycins inhibit bacterial RNA polymerase and are central in tuberculosis regimens and selected hardware-associated staphylococcal infections, but resistance emerges rapidly with monotherapy. Metronidazole is reduced in anaerobic organisms and protozoa to reactive intermediates that damage DNA; it covers anaerobes but not aerobes. Nitrofurantoin damages bacterial macromolecules after intracellular activation and is a bladder drug, not a pyelonephritis or bacteremia drug.

• Fluoroquinolones: oral step-down potential, atypical coverage for respiratory agents, and gram-negative activity; watch tendons, CNS, QT, aortic, dysglycemia, and C. difficile risks.
• Rifampin: never use alone for active staphylococcal infection or TB because resistance emerges quickly.
• Metronidazole: anaerobes below the diaphragm and selected protozoa; no aerobic gram-negative coverage.
• Nitrofurantoin: lower UTI only when renal function and organism susceptibility support use.

Folate pathway inhibition is sequential blockade

Trimethoprim-sulfamethoxazole combines two steps in bacterial folate metabolism: sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase. The combination can treat selected urinary, skin, Pneumocystis, Nocardia, Stenotrophomonas, and other infections when susceptibility and syndrome fit. Toxicities include rash, severe cutaneous reactions, hyperkalemia, renal effects, cytopenias, hepatitis, and drug interactions. Its broad usefulness makes it tempting, but local resistance and host contraindications matter.

• TMP-SMX is not one target; it is sequential folate pathway blockade.
• Hyperkalemia risk rises with kidney disease, ACE inhibitors/ARBs, spironolactone, and higher doses.
• Pneumocystis therapy uses much higher dosing than routine cystitis regimens.
• Always interpret through syndrome, susceptibility, allergy history, renal function, and interacting medications.

Membrane-active agents are reserved tools, not routine broadening

Daptomycin and polymyxins are often grouped as membrane-active drugs, but their clinical use is very different. Daptomycin targets gram-positive membranes and is used for selected MRSA and VRE syndromes outside pneumonia. Polymyxins such as colistin and polymyxin B bind gram-negative outer membrane lipopolysaccharide and are now generally reserved for difficult resistant gram-negative infections because toxicity and outcome concerns are substantial. These drugs should trigger careful syndrome, susceptibility, and toxicity review rather than reflexive escalation.

• Daptomycin: gram-positive; bactericidal; not pneumonia; monitor CPK.
• Polymyxins: gram-negative outer membrane activity; nephrotoxicity and neurotoxicity matter.
• Do not confuse membrane activity with universal activity; organism and site still decide usefulness.
• When polymyxins are being considered, reassess source control and newer beta-lactam options.

Class choice must include site, toxicity, and oral bioavailability

The final antimicrobial choice is a clinical decision, not a drug-class quiz. Ask whether the drug reaches the site, whether source control has occurred, whether oral therapy can achieve comparable exposure, whether the toxicity profile fits the host, and whether the drug's spectrum is unnecessarily broad. High-bioavailability oral agents such as fluoroquinolones, TMP-SMX, doxycycline, linezolid, metronidazole, and fluconazole can be excellent step-down drugs when the syndrome, isolate, and patient are appropriate. Conversely, a susceptible result does not rescue a drug with the wrong site profile.

• Meningitis, endocarditis, bacteremia, pneumonia, cystitis, abscess, and osteomyelitis each impose different exposure requirements.
• Oral step-down is about exposure and syndrome fit, not about whether IV therapy feels stronger.
• Avoid treating colonization: no mechanism of action is helpful when there is no infection.
• Dose and duration are part of the antimicrobial decision, not afterthoughts.

Guidelines

• Sanford Guide to Antimicrobial TherapyAntimicrobial class and syndrome treatment reference, current edition.Practical bedside reference for class selection, dosing, and syndrome-specific therapy.

Reviews

• Action and resistance mechanisms of antibiotics: a guide for cliniciansKapoor G, Saigal S, Elongavan A. J Anaesthesiol Clin Pharmacol. 2017;33(3):300-305. PMID: 29109626. DOI: 10.4103/joacp.JOACP_349_15.Accessible clinician review of major antibiotic classes, mechanisms of action, and resistance concepts.

Books & reference

• Mandell, Douglas, and Bennett's Principles and Practice of Infectious DiseasesAntimicrobial therapy chapters, current edition.Textbook reference for antimicrobial class pharmacology, spectrum, mechanisms, and syndrome-based use.